Marimed (MRMD) Liabilities and Shareholders Equity (2011 - 2026)

Marimed (MRMD) has reported Liabilities and Shareholders Equity for 16 consecutive years, with $201.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 3.28% year-over-year to $201.2 million; the TTM figure through Mar 2026 stood at $608.1 million (down 27.28% YoY), while the FY2025 annual figure was $202.6 million, down 2.14% from the prior year.
• Liabilities and Shareholders Equity retreated to $201.2 million in Q1 2026 per MRMD's latest filing, from $202.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $212.7 million in Q3 2024 and bottomed at $5000.0 in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $175.1 million across 5 years, with a median of $196.1 million in 2023.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 52.23% — and 2025, when it slumped 100.0%.
• Marimed's Liabilities and Shareholders Equity stood at $152.2 million in 2022, then rose by 28.86% to $196.1 million in 2023, then advanced by 5.54% to $207.0 million in 2024, then fell by 2.14% to $202.6 million in 2025, then decreased by 0.68% to $201.2 million in 2026.
• Business Quant data shows MRMD's Liabilities and Shareholders Equity at $201.2 million in Q1 2026, $202.6 million in Q4 2025, and $5000.0 in Q3 2025.